Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
two-component acellular pertussis vaccine
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
The two-component acellular pertussis vaccine is an investigational biologic vaccine developed by SmithKline Beecham (now GSK) for the prevention of pertussis (whooping cough). It contains two purified antigens from *Bordetella pertussis*: 25 μg of pertussis toxin (PT) inactivated by glutaraldehyde and formalin, and 25 μg of formalin-treated filamentous hemagglutinin (FHA). Typically formulated as a diphtheria-tetanus-acellular pertussis (DTaP) combination, it was evaluated in large-scale clinical trials in Sweden during the 1990s. Although it demonstrated a protective efficacy of 58.9% against laboratory-confirmed pertussis, it was found to be less effective than five-component acellular vaccines and was never commercialized for clinical use.
- Other names
- SKB acellular pertussis vaccineSmithKline Beecham two-component acellular pertussis vaccine
02
Targets
FHA (Filamentous hemagglutinin)
Beyond the preview
Go deeper on two-component acellular pertussis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on two-component acellular pertussis vaccine.